ArticleScientific reports2026
Constrained RNA polymerase mutational pathways distinguish corallopyronin A resistance from rifampicin resistance in staphylococci.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Corallopyronin A (CorA) is a natural RNA polymerase (RNAP) inhibitor active against Gram-positive pathogens, including Staphylococcus aureus. Although spontaneous resistance to CorA occurs less frequently than to rifampicin, the genetic basis and evolutionary constraints of CorA resistance remain incompletely defined. Spontaneous mutation frequencies to CorA and rifampicin were determined by fluctuation analysis in three S. aureus strains and two coagulase-negative staphylococci (CNS). Resistant mutants were phenotypically characterized and subjected to whole-genome sequencing. Double-resistant mutants were generated under rifampicin selection. Fitness costs were assessed by direct competition assays. Mutation frequencies to CorA were consistently lower than to rifampicin across all tested strains (Rif/CorA ratios 2.3-2.7). Whole-genome sequencing of 41 independently derived CorA-resistant mutants revealed resistance-associated substitutions confined to the RNAP subunits RpoB and RpoC. The mutational landscape was highly restricted, with recurrent hotspots at RpoC K334 and RpoB S1127. In coagulase-negative staphylococci (CNS), resistance remained RNAP-centred but displayed broader allelic diversity, including substitutions previously described in S. aureus but identified here for the first time in CNS species, as well as the previously undescribed RpoC D810Y substitution. Ten mutants with resistance to CorA and rifampicin retained the CorA-associated mutation and acquired additional rifampicin resistance substitutions at non-overlapping RNAP residues. CorA resistance imposed a moderate fitness cost (12-15%), while additional rifampicin resistance resulted in mutation-dependent increases in the fitness burden. CorA resistance in staphylococci arises at lower spontaneous frequencies than rifampicin resistance and is mediated by a constrained set of RNAP mutations. The restricted mutational landscape and associated fitness costs indicate that, under the in vitro conditions examined, CorA resistance arises through more constrained evolutionary pathways than rifampicin resistance. These findings provide a foundation for further evaluation of CorA as an RNA polymerase-targeting antimicrobial.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.